Renal Cancer The Lancet Dr David N Cade, Chief Medical Officer at Telix said, “The results of the ZIRCON trial make a compelling case for TLX250-CDx as a breakthrough product for kidney cancer imaging, and validate CAIX as Telix (ASX:TLX) has announced that the primary results from its Phase 3 ZIRCON trial have been published in The Lancet OncologyThe publication
Renal Cell Carcinoma The Lancet The addition of nivolumab (Opdivo) to tivozanib (Fotivda) compared with tivozanib alone failed to improve outcomes as second- or third-line treatment for patients with renal cell carcinoma (RCC) who A Victorian-developed imaging tool is set to change how kidney cancer is diagnosed and treated globally following its success in clinical trials Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world "The results of the ZIRCON trial make a compelling case for TLX250-CDx as a breakthrough product for kidney cancer imaging, and validate CAIX as a novel target to accurately identify renal cell
Renal Cancer The Lancet Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world "The results of the ZIRCON trial make a compelling case for TLX250-CDx as a breakthrough product for kidney cancer imaging, and validate CAIX as a novel target to accurately identify renal cell Diagnosis and treatment are limited by current imaging techniques, and renal mass biopsy is invasive most common and aggressive form of kidney cancer, and delays in diagnosis can significantly 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON [1] trial have been published in The Lancet 1 Zirconium in Renal Cancer Oncology, ClinicalTrialsgov ID 2019 5 Shuch et al Lancet Oncology 2024 6 Telix ASX disclosure 20 December 2021 7 Telix ASX disclosure 2 November 2021 Dr David N Cade, Chief Medical Officer at Telix said, "The results of the ZIRCON trial make a compelling case for TLX250-CDx as a breakthrough product for kidney cancer imaging, and validate CAIX as
Comments are closed.